Steroid Receptor Imaging in Breast Cancer

PET Clinics

Volumn 1, Issue 1, 2006, Pages 51-70

  Beauregard, Jean Mathieu ^a   Turcotte, Éric ^a   Bénard, François ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547704569     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2005.09.006     Document Type: Review

References (134)

1. Fisher B., Osborne K., Margolese R., et al. Neoplasms of the breast. In: Holland J., Blast R., Morton D., et al. (Eds). Cancer Medicine. 4th edition vol 1 (1997), Williams & Wilkins, Baltimore (MD) 2349-2429
2. Ray S., Rastogi R., and Kumar A. Current status of estrogen receptors. In: Jucker E. (Ed). Progress in drug research, vol 59 (2002), Birkhäuser Verlag, Basel (Switzerland) 201-232
3. Toft D., and Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterization. Proc Natl Acad Sci USA 55 6 (1966) 1574-1581
4. Greene G.L., Gilna P., Waterfield M., et al. Sequence and expression of human estrogen receptor complementary DNA. Science 231 4742 (1986) 1150-1154
5. Mosselman S., Polman J., and Dijkema R. ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett 392 1 (1996) 49-53
6. Pearce S.T., and Jordan V.C. The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 50 1 (2004) 3-22
7. Speirs V., Carder P.J., Lane S., et al. Oestrogen receptor [beta]: what it means for patients with breast cancer. Lancet Oncol 5 3 (2004) 174-181
8. Clarke R.B., Anderson E., and Howell A. Steroid receptors in human breast cancer. Trends Endocrinol Metab 15 7 (2004) 316-323
9. Osborne C.K., and Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications. J Clin Oncol 23 8 (2005) 1616-1622
10. Balfe P.J., McCann A.H., Welch H.M., et al. Estrogen receptor beta and breast cancer. Eur J Surg Oncol 30 10 (2004) 1043-1050
11. Keen J.C., and Davidson N.E. The biology of breast carcinoma. Cancer 97 3 (2003) 825-833
12. Mote P.A., Bartow S., Tran N., et al. Loss of co-ordinate expression of progesterone receptors A and B is an early event in breast carcinogenesis. Breast Cancer Res Treat 72 2 (2002) 163-172
13. Tait J.F., and Tait S.A. The effect of plasma protein binding on the metabolism of steroid hormones. J Endocrinol 131 3 (1991) 339-357
14. Siiteri P.K., Murai J.T., Hammond G.L., et al. The serum transport of steroid hormones. Recent Prog Horm Res 38 (1982) 457-510
15. Strel'chyonok O.A., and Avvakumov G.V. Specific steroid-binding glycoproteins of human blood plasma: novel data on their structure and function. J Steroid Biochem 35 5 (1990) 519-534
16. Hryb D.J., Khan M.S., Romas N.A., et al. The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones. J Biol Chem 265 11 (1990) 6048-6054
17. Osborne C.K. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51 3 (1998) 227-238
18. Henderson I.C., and Patek A.J. The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52 1-3 (1998) 261-288
19. Yasui Y., and Potter J.D. The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Control 10 5 (1999) 431-437
20. Anderson W.F., Chatterjee N., Ershler W.B., et al. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76 1 (2002) 27-36
21. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 9114 (1998) 1451-1467
22. Overgaard M. Radiotherapy as part of a multidisciplinary treatment strategy in early breast cancer. Eur J Cancer 37 Suppl 7 (2001) S33-S43
23. Olson J.E., Neuberg D., Pandya K.J., et al. The role of radiotherapy in the management of operable locally advanced breast carcinoma: results of a randomized trial by the Eastern Cooperative Oncology Group. Cancer 79 6 (1997) 1138-1149
24. Harvey J.M., Clark G.M., Osborne C.K., et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 5 (1999) 1474-1481
25. Bardou V.J., Arpino G., Elledge R.M., et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21 10 (2003) 1973-1979
26. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 8785 (1992) 71-85
27. Goldhirsch A., Glick J.H., Gelber R.D., et al. International consensus panel on the treatment of primary breast cancer. V: Update 1998. Recent Results Cancer Res 152 (1998) 481-497
28. Abrams J.S. Adjuvant therapy for breast cancer-results from the USA consensus conference. Breast Cancer 8 4 (2001) 298-304
29. Ferno M., Stal O., Baldetorp B., et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group. Breast Cancer Res Treat 59 1 (2000) 69-76
30. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst Monogr 30 (2001) 5-15
31. Fisher B., Dignam J., Bryant J., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88 21 (1996) 1529-1542
32. Colleoni M., Li S., Gelber R.D., et al. Timing of CMF chemotherapy in combination with tamoxifen in postmenopausal women with breast cancer: role of endocrine responsiveness of the tumor. Ann Oncol 16 5 (2005) 716-725
33. Bonneterre J., Buzdar A., Nabholtz J.M., et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92 9 (2001) 2247-2258
34. Nabholtz J.M., Bonneterre J., Buzdar A., et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 39 12 (2003) 1684-1689
35. Geisler J., Haynes B., Anker G., et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 3 (2002) 751-757
36. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 11 (2004) 1081-1092
37. Baum M., Buzdar A., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98 9 (2003) 1802-1810
38. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 19 (2003) 1793-1802
39. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Obstet Gynecol Surv 60 5 (2005) 307-309
40. Kahlert S., von Koch F., Ditsch N., et al. [Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results]. Gynakol Geburtshilfliche Rundsch 44 2 (2004) 102-112
41. Simpson D., Curran M.P., and Perry C.M. Letrozole: a review of its use in postmenopausal women with breast cancer. Drugs 64 11 (2004) 1213-1230
42. Bast Jr. R.C., Ravdin P., Hayes D.F., et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 6 (2001) 1865-1878
43. Parker M.G. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res Treat 26 2 (1993) 131-137
44. Webb P., Nguyen P., and Kushner P.J. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. J Biol Chem 278 9 (2003) 6912-6920
45. Pink J.J., and Jordan V.C. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res 56 10 (1996) 2321-2330
46. Howell A., Osborne C.K., Morris C., et al. ICI 182,780 (Faslodex): Development of a novel, pure antiestrogen. Cancer 89 4 (2000) 817-825
47. Wakeling A.E., and Bowler J. Ici 182,780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 43 1-3 (1992) 173-177
48. Mauriac L., Pippen J.E., Quaresma Albano J., et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 39 9 (2003) 1228-1233
49. Menard S., Fortis S., Castiglioni F., et al. HER2 as a prognostic factor in breast cancer. Oncology 61 Suppl 2 (2001) 67-72
50. Duffy M.J. Predictive markers in breast and other cancers: a review. Clin Chem 51 3 (2005) 494-503
51. Borg A., Baldetorp B., Ferno M., et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 81 2 (1994) 137-144
52. Arpino G., Green S.J., Allred D.C., et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10 17 (2004) 5670-5676
53. Agrup M., Stal O., Olsen K., et al. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 63 1 (2000) 23-29
54. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 13 (2000) 3159-3167
55. Piccart M.J., Di Leo A., and Hamilton A. HER2. a 'predictive factor' ready to use in the daily management of breast cancer patients?. Eur J Cancer 36 14 (2000) 1755-1761
56. Yamauchi H., Stearns V., and Hayes D.F. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. J Clin Oncol 19 8 (2001) 2334-2356
57. Winston J.S., Ramanaryanan J., and Levine E. HER-2/neu evaluation in breast cancer are we there yet?. Am J Clin Pathol 121 Suppl (2004) S33-S49
58. Piccart M.J., and Awada A. State-of-the-art chemotherapy for advanced breast cancer. Semin Oncol 27 5, Suppl 9 (2000) 3-12
59. Ellis M.J., Coop A., Singh B., et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19 18 (2001) 3808-3816
60. Ellis M.J., Coop A., Singh B., et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 63 19 (2003) 6523-6531
61. Hull D., Clark G., Osborne C., et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res 43 (1983) 413-416
62. Castagnetta L., Traina A., DiCarlo A., et al. Heterogeneity of soluble and nuclear oestrogen receptor status of involved nodes in relation to primary breast cancer. Eur J Cancer Clin Oncol 23 (1987) 31-35
63. Johnston S., Saccani-Jotti G., Smith E., et al. Changes in estrogen receptor, progesteron receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55 (1995) 3331-3338
64. Encarnacion C., Ciocca D., McGuire W., et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26 (1993) 237-246
65. Johnston S., Haynes B., Smith I., et al. Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration. Lancet 342 (1993) 1521-1522
66. Hochberg R.B. Iodine-125-labeled estradiol: a gamma-emitting analog of estradiol that binds to the estrogen receptor. Science 205 4411 (1979) 1138-1140
67. Pavlik E.J., Nelson K., Gallion H.H., et al. Characterization of high specific activity [16 alpha-123I]Iodo-17 beta-estradiol as an estrogen receptor-specific radioligand capable of imaging estrogen receptor-positive tumors. Cancer Res 50 24 (1990) 7799-7805
68. Schober O., Scheidhauer K., Jackisch C., et al. Breast cancer imaging with radioiodinated oestradiol. Lancet 335 8704 (1990) 1522
69. Kenady D.E., Pavlik E.J., Nelson K., et al. Images of estrogen-receptor-positive breast tumors produced by estradiol labeled with iodine I 123 at 16 alpha. Arch Surg 128 12 (1993) 1373-1381
70. Scheidhauer K., Muller S., Smolarz K., et al. Tumor-Szintigraphie mit 123J-markiertem Ostradiol beim Mammakarzinom-Rezeptorszintigraphie [Tumor scintigraphy using 123I-labeled estradiol in breast cancer-receptor scintigraphy]. Nucl Med (Stuttg) 30 3 (1991) 84-99 [in German]
71. Symes E.K., Coulson W.F., and Ralphs D.N. The synthesis of 16 alpha-[131I]iodo-oestradiol and evaluation of its use as a radiotracer for oestrogen receptor positive breast tumours. J Steroid Biochem 22 2 (1985) 155-160
72. Gatley S.J., Shaughnessy W.J., Inhorn L., et al. Studies with 17 beta(16 alpha-[125i]iodo)-estradiol, an estrogen receptor-binding radiopharmaceutical, in rats bearing mammary tumors. J Nucl Med 22 5 (1981) 459-464
73. Ali H., Rousseau J., Ghaffari M.A., et al. Synthesis, receptor binding, and tissue distribution of (17 alpha,20E)- and (17 alpha,20Z)-21-[125I]iodo-19-norpregna-1,3,5(10), 20-tetraene-3,17-diol. J Med Chem 31 10 (1988) 1946-1950
74. Ali H., Rousseau J., Ghaffari M.A., et al. Synthesis, receptor binding, and tissue distribution of 7 alpha- and 11 beta-substituted (17 alpha,20E)- and (17 alpha,20Z)-21-[125I]iodo-19-norpregna-1,3,5(10),20-tetraene-3,17-dio ls. J Med Chem 34 2 (1991) 854-860
75. Foulon C., Guilloteau D., Baulieu J.L., et al. Estrogen receptor imaging with 17 alpha-[123I]iodovinyl-11 beta-methoxyestradiol (MIVE2)-Part I. Radiotracer preparation and characterization. Int J Rad Appl Instrum B 19 3 (1992) 257-261
76. Ribeiro-Barras M.J., Foulon C., Baulieu J.L., et al. Estrogen receptor imaging with 17 alpha-[123I]iodovinyl-11 beta-methoxyestradiol (MIVE2)-Part II. Preliminary results in patients with breast carcinoma. Int J Rad Appl Instrum B 19 3 (1992) 263-267
77. Rijks L.J., Boer G.J., Endert E., et al. The stereoisomers of 17alpha-[123I]iodovinyloestradiol and its 11beta-methoxy derivative evaluated for their oestrogen receptor binding in human MCF-7 cells and rat uterus, and their distribution in immature rats. Eur J Nucl Med 23 3 (1996) 295-307
78. Rijks L.J., Boer G.J., Endert E., et al. The Z-isomer of 11 beta-methoxy-17 alpha-[123I]iodovinylestradiol is a promising radioligand for estrogen receptor imaging in human breast cancer. Nucl Med Biol 24 1 (1997) 65-75
79. Rijks L.J., Bakker P.J., van Tienhoven G., et al. Imaging of estrogen receptors in primary and metastatic breast cancer patients with iodine-123-labeled Z-MIVE. J Clin Oncol 15 7 (1997) 2536-2545
80. Nachar O., Rousseau J.A., Lefebvre B., et al. Biodistribution, dosimetry and metabolism of 11beta-methoxy-(17alpha,20E/Z)-[123I]iodovinylestradiol in healthy women and breast cancer patients. J Nucl Med 40 10 (1999) 1728-1736
81. Nachar O., Rousseau J.A., Ouellet R., et al. Scintimammography with 11beta-methoxy-(17alpha,20Z)-[123I]iodovinylestradiol: a complementary role to 99mTc-methoxyisobutyl isonitrile in the characterization of breast tumors. J Nucl Med 41 8 (2000) 1324-1331
82. Bennink M.L., Leuba S.H., Leno G.H., et al. Unfolding individual nucleosomes by stretching single chromatin fibers with optical tweezers. Nat Struct Biol 8 7 (2001) 606-610
83. Bennink R.J., van Tienhoven G., Rijks L.J., et al. In vivo prediction of response to antiestrogen treatment in estrogen receptor-positive breast cancer. J Nucl Med 45 1 (2004) 1-7
84. Ali H., Rousseau J., and van Lier J.E. Synthesis of A-ring fluorinated derivatives of (17 alpha,20E/Z)-[125I]iodovinylestradiols: effect on receptor binding and receptor-mediated target tissue uptake. J Med Chem 36 21 (1993) 3061-3072
85. Ali H., Rousseau J., and van Lier J.E. 7 alpha-Methyl- and 11 beta-ethoxy-substitution of [125I]-16 alpha-iodoestradiol: effect on estrogen receptor-mediated target tissue uptake. J Med Chem 36 2 (1993) 264-271
86. Ali H., Rousseau J., Gantchev T.G., et al. 2- and 4-fluorinated 16 alpha(-)[125I]iodoestradiol derivatives: synthesis and effect on estrogen receptor binding and receptor-mediated target tissue uptake. J Med Chem 36 26 (1993) 4255-4263
87. Ali H., Rousseau J., and van Lier J.E. Synthesis, receptor binding and biodistribution of the gem-21-chloro-21-iodovinylestradiol derivatives. J Steroid Biochem Mol Biol 46 5 (1993) 613-622
88. Ali H., Rousseau J., Paquette B., et al. Synthesis and biological properties of 7alpha-cyano derivatives of the (17alpha,20E/Z)-[125I]iodovinyl- and 16alpha-[125I]iodo-estradiols. Steroids 68 14 (2003) 1189-1200
89. Rijks L.J., van den Bos J.C., van Doremalen P.A., et al. Synthesis, estrogen receptor binding, and tissue distribution of a new iodovinylestradiol derivative (17alpha,20E)-21-[123I]Iodo-11beta-nitrato-19-norp regna-1,3,5 (10),20-tetraene-3,17-diol (E-[123I]NIVE). Nucl Med Biol 25 4 (1998) 411-421
90. Cummins C.H. Radiolabeled steroidal estrogens in cancer research. Steroids 58 6 (1993) 245-259
91. McElvany K.D., Katzenellenbogen J.A., Shafer K.E., et al. 16 alpha-[77Br]bromoestradiol: dosimetry and preliminary clinical studies. J Nucl Med 23 5 (1982) 425-430
92. McElvany K.D., Carlson K.E., Welch M.J., et al. In vivo comparison of 16 alpha[77Br]bromoestradiol-17 beta and 16 alpha-[125I]iodoestradiol-17 beta. J Nucl Med 23 5 (1982) 420-424
93. Strickland L.A., Ponce Y.Z., Hunter D.H., et al. Amino and iodotamoxifens: synthesis, estrogen receptor affinity and biodistribution. Drug Des Deliv 6 3 (1990) 195-212
94. Maaroufi Y., Quivy J., Trivedi S., et al. 4-iodotamoxifen aziridine, a new affinity labeling agent for the rapid detection of estrogen receptor isoforms. J Steroid Biochem Mol Biol 67 2 (1998) 95-104
95. Hanson R.N., and Seitz D.E. Tissue distribution of the radiolabeled antiestrogen [125I]iodotamoxifen. Int J Nucl Med Biol 9 2 (1982) 105-107
96. Yang D.J., Li C., Kuang L.R., et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 55 1 (1994) 53-67
97. Van de Wiele C., De Vos F., De Sutter J., et al. Biodistribution and dosimetry of (iodine-123)-iodomethyl-N, N-diethyltamoxifen, an (anti)oestrogen receptor radioligand. Eur J Nucl Med 26 10 (1999) 1259-1264
98. Van de Wiele C., Cocquyt V., VandenBroecke R., et al. Iodine-labeled tamoxifen uptake in primary human breast carcinoma. J Nucl Med 42 12 (2001) 1818-1820
99. Skaddan M.B., Wust F.R., Jonson S., et al. Radiochemical synthesis and tissue distribution of Tc-99m-labeled 7alpha-substituted estradiol complexes. Nucl Med Biol 27 3 (2000) 269-278
100. Unak P., Enginar H., Biber F.Z., et al. A correlative study between 99mTc-ESTCPTA and 99mTc-MIBI in rats. Appl Radiat Isot 57 5 (2002) 733-742
101. Hunter D.H., and Luyt L.G. Single isomer technetium-99m tamoxifen conjugates. Bioconjug Chem 11 2 (2000) 175-181
102. Ouellet R., Rousseau J., Brasseur N., et al. Synthesis, receptor binding, and target-tissue uptake of carbon-11 labeled carbamate derivatives of estradiol and hexestrol. J Med Chem 27 4 (1984) 509-513
103. Dence C.S., Napolitano E., Katzenellenbogen J.A., et al. Carbon-11-labeled estrogens as potential imaging agents for breast tumors. Nucl Med Biol 23 4 (1996) 491-496
104. Ali H., Rousseau J., Diksic M., et al. Synthesis, receptor binding and target-tissue uptake of carbon-11-labeled carbamate derivatives of estradiol and hexestrol. Int J Rad Appl Instrum B 19 2 (1992) 175-182
105. Ram S., and Spicer L.D. Direct Incorporation of [C-11] Carbon Dioxide for Labeling Bioactive Molecules - an Application to [C-11] Labeled Tamoxifen. J Labelled Comp Radiopharm 27 6 (1989) 661-668
106. Kiesewetter D., Kilbourn M., Landvatter S., et al. Preparation of four fluorine-18-labeled estrogens and their selective uptake in target tissues of immature rats. J Nucl Med 25 11 (1984) 1212-1221
107. Mathias C.J., Welch M.J., Katzenellenbogen J.A., et al. Characterization of the uptake of 16 alpha-([18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors. Int J Rad Appl Instrum B 14 1 (1987) 15-25
108. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer: PET imaging of estrogen receptors. Radiology 169 1 (1988) 45-48
109. Mankoff D.A., Peterson L.M., Tewson T.J., et al. [18F]fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med 42 4 (2001) 679-684
110. Mankoff D.A., Tewson T.J., and Eary J.F. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES). Nucl Med Biol 24 4 (1997) 341-348
111. Lim J.L., Zheng L., Berridge M.S., et al. The use of 3-methoxymethyl-16 beta, 17 beta-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16 alpha-fluoroestradiol. Nucl Med Biol 23 7 (1996) 911-915
112. Romer J., Fuchtner F., Steinbach J., et al. Automated production of 16alpha-[18F]fluoroestradiol for breast cancer imaging. Nucl Med Biol 26 4 (1999) 473-479
113. Pomper M.G., VanBrocklin H., Thieme A.M., et al. 11 beta-methoxy-, 11 beta-ethyl- and 17 alpha-ethynyl-substituted 16 alpha-fluoroestradiols: receptor-based imaging agents with enhanced uptake efficiency and selectivity. J Med Chem 33 12 (1990) 3143-3155
114. VanBrocklin H.F., Carlson K.E., Katzenellenbogen J.A., et al. 16 beta-([18F]fluoro)estrogens: systematic investigation of a new series of fluorine-18-labeled estrogens as potential imaging agents for estrogen-receptor-positive breast tumors. J Med Chem 36 11 (1993) 1619-1629
115. VanBrocklin H.F., Rocque P.A., Lee H.V., et al. 16 beta-[18F]fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors. Life Sci 53 10 (1993) 811-819
116. Jonson S.D., Bonasera T.A., Dehdashti F., et al. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes. Nucl Med Biol 26 1 (1999) 123-130
117. Seimbille Y., Bénard F., and van Lier J.E. Synthesis of 16alpha-fluoro ICI 182,780 derivatives: powerful antiestrogens to image estrogen receptor densities in breast cancer by positron emission tomography. J Chem Soc [Perkin 1] 20 (2002) 2275-2281
118. Seimbille Y., Rousseau J., Benard F., et al. 18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals. Steroids 67 9 (2002) 765-775
119. Bénard F., Aliaga A., Ahmed N., et al. Biodistribution of fluorinated estradiol derivatives in ER + tumor-bearing mice: impact of substituents, formulation and specific activity [abstract]. J Nucl Med 45 5 (2004) 329P
120. Inoue T., Kim E.E., Wallace S., et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 11 4 (1996) 235-245
121. Landvatter S.W., Kiesewetter D.O., Kilbourn M.R., et al. (2R*, 3S*)-1-[18F]fluoro-2,3-bis(4-hydroxyphenyl)pentane [(18F]fluoronor-hexestrol), a positron-emitting estrogen that shows highly-selective, receptor-mediated uptake by target tissues in vivo. Life Sci 33 19 (1983) 1933-1938
122. Hostetler E.D., Jonson S.D., Welch P.J., et al. Synthesis of 2-[F-18]fluoroestradiol, a potential diagnostic imaging agent for breast cancer: Strategies to achieve nucleophilic substitution of an electron-rich aromatic ring with [F-18]F-. J Org Chem 64 1 (1999) 178-185
123. Seimbille Y., Benard F., Rousseau J., et al. Impact on estrogen receptor binding and target tissue uptake of [18F]fluorine substitution at the 16[alpha]-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol 31 6 (2004) 691-698
124. Pomper M.G., Katzenellenbogen J.A., Welch M.J., et al. 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone: synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography. J Med Chem 31 7 (1988) 1360-1363
125. Dehdashti F., McGuire A.H., Van Brocklin H.F., et al. Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 32 8 (1991) 1532-1537
126. Jonson S.D., and Welch M.J. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins. Q J Nucl Med 42 1 (1998) 8-17
127. Ali H., Rousseau J., Ahmed N., et al. Synthesis of the 7alpha-cyano-(17alpha,20E/Z)-[125I]iodovinyl-19-nortestosterones: potential radioligands for androgen and progesterone receptors. Steroids 68 14 (2003) 1163-1171
128. Rijks L.J., van den Bos J.C., van Doremalen P.A., et al. New iodinated progestins as potential ligands for progesterone receptor imaging in breast cancer. Part 2: In vivo pharmacological characterization. Nucl Med Biol 25 8 (1998) 791-798
129. Katzenellenbogen J.A. Designing steroid receptor-based radiotracers to image breast and prostate tumors. J Nucl Med 36 Suppl 6 (1995) 8S-13S
130. McGuire A.H., Dehdashti F., Siegel B.A., et al. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 32 8 (1991) 1526-1531
131. Dehdashti F., Mortimer J.E., Siegel B.A., et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36 10 (1995) 1766-1774
132. Mortimer J.E., Dehdashti F., Siegel B.A., et al. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol 19 11 (2001) 2797-2803
133. Mankoff D.A., Peterson L.M., Petra P.H., et al. Factors affecting the level and heterogeneity of uptake of [18F]Fluoroestradiol in patients with estrogen receptor positive breast cancer [abstract]. J Nucl Med 43 5 (2002) 286P
134. Linden H.M., Stekhova S., Link J.M., et al. HER2 expression and uptake of 18F-Fluoroestradiol (FES) predict response of breast cancer to hormonal therapy [abstract]. J Nucl Med 45 5 (2004) 85P